Brief: Allena Pharmaceuticals Provides Updates On Reloxaliase Development Program And Corporate Activities

Allena Pharmaceuticals

04/12/2019 22:53

Dec 4 (Reuters) - Allena Pharmaceuticals Inc  ALNA.O :
    * ALLENA PHARMACEUTICALS PROVIDES UPDATES ON RELOXALIASE
DEVELOPMENT PROGRAM AND CORPORATE ACTIVITIES
    * ALLENA PHARMACEUTICALS - PLANS TO RE-ENGAGE WITH FDA, WITH
REQUEST TO DISCUSS MEASURES TO POTENTIALLY STREAMLINE ITS
ONGOING URIROX PROGRAM
    * ALLENA PHARMACEUTICALS INC - IMPLEMENTING MEASURES TO
REDUCE
EXPENSES AND PRESERVE CAPITAL FOR RELOXALIASE PROGRAMS
    * ALLENA PHARMACEUTICALS INC - EXPECTS TO MEET WITH FDA IN
EARLY
2020
    * ALLENA PHARMACEUTICALS - WILL LIMIT OPENING OF NEW TRIAL
SITES
FOR ITS ONGOING URIROX-2 TRIAL AND CONTINUE TO ENROLL PATIENTS
AT EXISTING SITES
    * ALLENA PHARMACEUTICALS INC - WILL DELAY ADDITIONAL PLANNED
INVESTMENTS IN MANUFACTURING
    * ALLENA PHARMACEUTICALS - WILL IMPLEMENT REDUCTION IN
WORKFORCE
THAT WILL LEAD TO ABOUT 30 PERCENT REDUCTION IN SALARY & RELATED
COMPENSATION EXPENSES
    * ALLENA PHARMACEUTICALS - EXPECTS CURRENT CASH & CASH
EQUIVALENTS
WILL BE SUFFICIENT TO FUND OPERATING EXPENSES, CAPEX
REQUIREMENTS INTO Q4 2020
    * ALLENA PHARMACEUTICALS INC - CONTINUES TO EXPLORE A RANGE
OF
POTENTIAL FINANCIAL ALTERNATIVES TO SUPPORT DEVELOPMENT OF
RELOXALIASE

Source text for Eikon:  ID:nGNXb1dd06 
Further company coverage:  ALNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))